Have a feature idea you'd love to see implemented?
Let us know!
Price (delayed)
$237.27
Market cap
$34.83B
P/E Ratio
31.38
Dividend/share
$2.02
EPS
$7.56
Enterprise value
$35.25B
ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea , chronic obstructive pulmonary disease , and other respiratory
Highlights
Resmed's debt has decreased by 43% YoY and by 2.7% QoQ
The EPS has increased by 23% YoY and by 9% from the previous quarter
The price to earnings (P/E) is 29% lower than the 5-year quarterly average of 44.0 but 6% higher than the last 4 quarters average of 29.7
Key stats
What are the main financial stats of RMD
Market
Valuations
Earnings
Shares outstanding
146.8M
Market cap
$34.83B
Enterprise value
$35.25B
Price to earnings (P/E)
31.38
Price to book (P/B)
6.71
Price to sales (P/S)
7.25
EV/EBIT
25.03
EV/EBITDA
21.69
EV/Sales
7.33
Revenue
$4.81B
Gross profit
$2.77B
Net income
$1.11B
EBIT
$1.41B
EBITDA
$1.62B
Free cash flow
$1.35B
Per share
Balance sheet
Liquidity
EPS
$7.56
EPS diluted
$7.55
Free cash flow per share
$9.21
Book value per share
$35.36
Revenue per share
$32.73
TBVPS
$26.27
Total assets
$7.22B
Total liabilities
$2.03B
Debt
$850.24M
Equity
$5.2B
Working capital
$1.74B
Debt to equity
0.16
Current ratio
2.92
Quick ratio
1.37
Net debt/EBITDA
0.26
Margins
Efficiency
Dividend
EBITDA margin
33.8%
Gross margin
57.7%
Net margin
23.1%
Operating margin
29.5%
Return on assets
16%
Return on equity
23.2%
Return on invested capital
39.6%
Return on capital employed
22.3%
Return on sales
29.3%
Dividend yield
0.85%
DPS
$2.02
Payout ratio
26.7%
RMD stock price
How has the Resmed stock price performed over time
Intraday
2.46%
1 week
-0.52%
1 month
-1.77%
1 year
36.39%
YTD
37.93%
QTD
-2.81%
Financial performance
How have Resmed's revenue and profit performed over time
Revenue
$4.81B
Gross profit
$2.77B
Operating income
$1.42B
Net income
$1.11B
Gross margin
57.7%
Net margin
23.1%
RMD's operating income is up by 24% YoY and by 7% QoQ
RMD's net income is up by 23% YoY and by 9% QoQ
The gross profit has grown by 15% YoY and by 4.4% from the previous quarter
RMD's operating margin is up by 13% year-on-year and by 4.6% since the previous quarter
Growth
What is Resmed's growth rate over time
Valuation
What is Resmed stock price valuation
P/E
31.38
P/B
6.71
P/S
7.25
EV/EBIT
25.03
EV/EBITDA
21.69
EV/Sales
7.33
The price to earnings (P/E) is 29% lower than the 5-year quarterly average of 44.0 but 6% higher than the last 4 quarters average of 29.7
The EPS has increased by 23% YoY and by 9% from the previous quarter
RMD's P/B is 26% below its 5-year quarterly average of 9.1 but 8% above its last 4 quarters average of 6.2
RMD's equity is up by 22% year-on-year and by 7% since the previous quarter
The P/S is 14% lower than the 5-year quarterly average of 8.4 but 13% higher than the last 4 quarters average of 6.4
The company's revenue rose by 10% YoY and by 2.6% QoQ
Efficiency
How efficient is Resmed business performance
The company's return on invested capital rose by 38% YoY and by 11% QoQ
The ROA has increased by 19% YoY and by 7% from the previous quarter
The ROS has increased by 10% YoY and by 4.6% from the previous quarter
Resmed's ROE has increased by 3.6% from the previous quarter and by 2.7% YoY
Dividends
What is RMD's dividend history
DPS
$2.02
Dividend yield
0.85%
Payout ratio
26.7%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Resmed financials performed over time
RMD's total liabilities is down by 19% year-on-year
Resmed's quick ratio has increased by 17% YoY and by 16% from the previous quarter
Resmed's debt is 84% lower than its equity
Resmed's debt to equity has shrunk by 54% YoY and by 11% QoQ
Resmed's debt has decreased by 43% YoY and by 2.7% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.